Introduction

24
Lassa fever is an acute and occasionally severe rodent-borne viral haemorrhagic fever, with 25 cases in humans geographically constrained to sub-Saharan West Africa. Discovered in 1969, 26 Lassa fever (LF) is endemic to much of rural Nigeria and the countries of the Mano River 27 Union (Sierra Leone, Guinea and Liberia; MRU) [1] . International interest in Lassa virus 28 (LASV) has often focused on global health security, since its long incubation period (usually 29 7-10 days) makes it one of the most commonly exported viral haemorrhagic fevers (VHFs) to 30 countries outside its endemic range [2] . As a result, LASV is now classified as a Select Agent 31 by the US Federal Select Agent Program, requiring Biosafety Level-4 conditions for 32 laboratory study [3] . In contrast, its contribution to the burden of disease in West Africa has 33 historically been under-appreciated, despite suggestions that it causes considerable annual 34 morbidity and mortality in some of Africa's poorest communities [1, 4] . Awareness of LF as a 35 public health issue is increasing, especially following the 2013-16 Ebola virus disease (EVD) 36 epidemic in the MRU, which has galvanized national and international agencies' attempts to 37 improve the prediction of and response to disease outbreaks in West Africa. In 2015, the 38 World Health Organisation listed LF among priority diseases requiring urgent research and 39 development attention [5] . In response, LASV was made a priority for vaccine development 40 funding by the multi-agency Coalition for Epidemic Preparedness Innovations (CEPI), 41 alongside several other emerging viruses [6] . 42 
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Despite growing interest in LF, our knowledge of its ecology, epidemiology and distribution 44 in West Africa is limited. For decades, disease surveillance has piggy-backed on biomedical 45 research projects based in districts where LF is already recognized as a problem. However, 46 previous seroprevalence studies have suggested high numbers of undiagnosed infections in 47 non-endemic areas [7] [8] [9] and, in recent years, official incidence reports have seen a In humans LASV causes a wide spectrum of disease manifestations, ranging from 71 asymptomatic infections to acute and severe disease. Onset of acute LF is gradual and 72 nonspecific, often beginning with intermittent fever and malaise followed by myalgia, sore These dynamics appear to be less strongly pronounced in studies from Guinea, where M. There is also increasing political will and institutional funding for VHF surveillance in 
